FDA 483 - Fresenius Kabi USA, LLC - March 06, 2015
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Fresenius Kabi USA, LLC in Grand Island, NY, revealed deficiencies in drug product manufacturing processes. Observations included a lack of established acceptable yield for bulk material and incomplete documentation of product loss, hindering process assessment. Additionally, the firm's environmental monitoring system in aseptic processing areas was found to be deficient, with re-testing performed without proper invalidation of original out-of-spec results.
ID · 5a97e654-80ca-4e64-89c7-e6f46bad9237